News

Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE’s Interleukin Receptor 7 Antagonist

GENEVA & NANTES, France–(BUSINESS WIRE) — Selexis SA and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) announced today the signing of a commercial license agreement that provides OSE Immunotherapeutics with access to high performance research cell banks (RCBs) from the Selexis SUREtechnology Platform™. The agreement builds upon previous collaboration between the two companies as announced in November 2016 and is designed to support the advancement of the clinical development of OSE’s interleukin receptor 7 antagonist, OSE-127 (Effi-7), under development as a potential treatment for inflammatory bowel diseases, such as ulcerative colitis.

2017-06-20T13:01:12+00:00